Perspectives for Induced Pluripotent Stem Cell Technology

New Insights Into Human Physiology Involved in Somatic Mosaicism

Naoki Nagata, Shinya Yamanaka

Abstract: Induced pluripotent stem cell technology makes in vitro reprogramming of somatic cells from individuals with various genetic backgrounds possible. By applying this technology, it is possible to produce pluripotent stem cells from biopsy samples of arbitrarily selected individuals with various genetic backgrounds and to subsequently maintain, expand, and stock these cells. From these induced pluripotent stem cells, target cells and tissues can be generated after certain differentiation processes. These target cells/tissues are expected to be useful in regenerative medicine, disease modeling, drug screening, toxicology testing, and proof-of-concept studies in drug development. Therefore, the number of publications concerning induced pluripotent stem cells has recently been increasing rapidly, demonstrating that this technology has begun to infiltrate many aspects of stem cell biology and medical applications. In this review, we discuss the perspectives of induced pluripotent stem cell technology for modeling human diseases. In particular, we focus on the cloning event occurring through the reprogramming process and its ability to let us analyze the development of complex disease-harboring somatic mosaicism. (Circ Res. 2014;114:505-510.)

Key Words: induced pluripotent stem cells ■ mosaicism

Induced pluripotent stem (iPS) cell technology involves the generation of pluripotent stem cells from adult somatic cells by the exogenous expression of specific reprogramming factors1,2 (see Box). This technology opened the door for us to access a robust platform demonstrating in vitro cellular reprogramming from certain somatic cells to pluripotent status.

Recently, Cahan and Daley3 conducted a bibliometric analysis of the pluripotent stem cells (including iPS cells, embryonic stem [ES] cells, and embryonic carcinoma cells) generated since 2010. They pointed out that the number of publications concerning iPS cells has increased, whereas the number of publications concerning the applications of pluripotent stem cells has increased. They pointed out that it is the increase in the studies of iPS cells that brought about this change in the research trend, because it gave scientists access to pluripotent stem cells with robust and reproducible technology. As Cahan and Daley3 have shown, iPS cells quickly became recognized as an innovative research tool for the study of biology and medicine. In this review, we focus on the cloning event occurring through the reprogramming process and its ability to let us analyze the development of complex disease-harboring somatic mosaicism.

Original received November 15, 2013; revision received December 27, 2013; accepted January 6, 2014. In December 2013, the average time from submission to first decision for all original research papers submitted to Circulation Research was 11.66 days.

From the Department of Reprogramming Science, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan (N.N., S.Y.); and Gladstone Institute of Cardiovascular Disease, San Francisco, CA (S.Y.).

Correspondence to Shinya Yamanaka, MD, PhD, Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan. E-mail yamanaka@cira.kyoto-u.ac.jp

© 2014 American Heart Association, Inc.

Circulation Research is available at http://circres.ahajournals.org

DOI: 10.1161/CIRCRESAHA.114.303043
Therefore, further improvement of the differentiation and differentiation protocols yield relatively immature cells.10–12

Cardiomyocytes differentiated from iPS cells using the current renewable way. However, there are still some limitations that nity to maintain specific somatic cells on a large scale and in a protocols, that is, these technologies can provide an opportu-
of cells can be prepared by using appropriate differentiation

<table>
<thead>
<tr>
<th>Nonstandard Abbreviations and Acronyms</th>
</tr>
</thead>
<tbody>
<tr>
<td>CINCA</td>
</tr>
<tr>
<td>DS</td>
</tr>
<tr>
<td>ES</td>
</tr>
<tr>
<td>IPS</td>
</tr>
</tbody>
</table>

Discovery of Induced Pluripotent Stem Cells

Induced pluripotent stem (iPS) cells are generated from mouse cells by the ectopic expression of key transcription factors (Oct3/4, Sox2, c-Myc, Klf4).1 The iPS cells were indistinguish-
able from embryonic stem cells in terms of their morphol-
ge, gene expression, self-renewal capacity, and pluripotency.
Therefore, under this process, the somatic memory of the subject cells was reprogrammed to the stage of blastocyst inner cells. Further experiments confirmed the contribution of iPS cells to mammalian (mouse) ontogenesis. The mouse iPS cells have been confirmed to have a chimeric contribution following blastocyst injection and have also been proven to have competency for the germ line.3,5

Subsequently, human iPS cells were established by 3 laborato-
aries at almost the same time using the same approaches.2,6,7 This shows that the iPS cell technology was already highly reproduc-
able and accessible to several laboratories and that these cells can be readily used to perform experiments in molecular biology and mammalian cell culture. These iPS cells met the criteria proposed for the definition of human embryonic stem cells, with the exception that the iPS cells are not derived from embryos.

iPS Cells for In Vitro Modeling of Native Physiological Conditions

Immortalized cells and primary cell lines have been the candidate cells used for creating human physiological models thus far. However, both of these types of cells are associated with serious defects when used for such purposes. Although immortalized cell lines can be maintained as homogenous cell populations at low cost, they lack important aspects of the native functions of cells. Likewise, although primary cell lines can provide fully differentiated cells that have a close approxima-
tion of the native function, the collection of all cell types is not possible because of the level of invasion required to collect them, and the limited proliferative activity of primary cells can make reproducing experiments difficult.9

On the contrary, human-derived iPS and ES cell lines can overcome these disadvantages. After the expansion of these pluripotent cell lines, a sufficient number of the desired types of cells can be prepared by using appropriate differentiation protocols, that is, these technologies can provide an opportunity to maintain specific somatic cells on a large scale and in a renewable way. However, there are still some limitations that need to be overcome. For example, it has been pointed out that cardiomyocytes differentiated from iPS cells using the current differentiation protocols yield relatively immature cells.10–12 Therefore, further improvement of the differentiation and maturation protocols will be needed to more accurately recap-

Human ES cells carrying mutation for some genetic disor-
ders have been reported (eg, Huntington disease, cystic fibro-
sis, myotonic dystrophy type 1, and Fragile X syndrome).13,14 However, there are certain ethical concerns associated with developing ES cells obtained from in vitro fertilization clinics for the study of genetic diseases.15 In contrast, such ethical issues are overcome with the use of disease-specific iPS cell lines, because they can be generated from somatic cells such as fibroblasts or peripheral blood cells, which can be collected by minimally invasive procedures and do not require the de-
struction of a human embryo.

iPS Cells From Arbitrarily Selected Individuals

Another advantage of using iPS cells in medical research is that this technology makes it possible to obtain human plu-
ripotent stem cells from arbitrarily selected individuals with various genetic backgrounds, including patients with various diseases. In 2008, the first patient-specific iPS cells were gen-
erated.16,17 Since then, abundant studies of disease models that represent the human condition with high fidelity have been reported,18,19 particularly those aiming to investigate diseases that are caused by a single gene mutation. In most of the stud-
ies, iPS cell lines from unaffected or healthy donors were used as controls. However, recent genome-wide association stud-
ies using a set of controls derived from different individuals showed significant experimental noise attributable to genomic variations. Moreover, these controls cannot really be defined as healthy, because each person carries 50 to 100 disease-associated genetic variations.20 One way to address these is-

issues is to obtain isogenic controls by correcting mutated genes in patient-specific iPS cell lines.21–27 The recent progresses in genetic engineering technologies, such as Transcription Activator-Like Effector Nuclease (TALEN) and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs), will facilitate this strategy.27,28

Somatic mutations can give rise to a broad range of diseases, including cancer, and noncancerous mosaic diseases.8 Recently, heterogeneous patient-specific iPS cell lines have been generated from the somatic cells of patients with various mosaic diseases, such as Down syndrome (DS),29–35 Fragile X syndrome,36 Rett syndrome,29,37,38 Fanconi anemia,41 and chronic infantile neurolog-
ic cutaneous and articular (CINCA) syndrome.42 Even though there are some limitations associated with the kinds of diseases that can be modeled, using iPS cells derived from patients with somatic mosaicism has an advantage in that it allows analyses with isogenic controls. In these cases, both mutant and wild-type iPS cell clones can be generated from the same patients. Each pair of clones theoretically has the same genetic background, ex-
cept for the altered chromosome or mutated gene(s) and should serve as an ideal pair of mutant and isogenic control clones, thereby allowing for highly reliable studies of the impact of the mutation. It should be mentioned that we could not completely exclude the introduction of new mutations during the induction of iPS cells and subsequent cultivation. The recently improved next-generation DNA sequencing and bioinformatics techniques should be useful in detecting such acquired mutations and in-
creasing the quality of experiments.
The following examples of patient-specific iPS cells generated from mosaic cases of DS and CINCA syndrome illustrate the advantage of using iPS cell technology for disease modeling.

**Somatic Mosaicism in DS**

DS is the most frequent form of mental retardation and is caused by autosomal trisomy of all or a critical portion of chromosome 21. Patients with DS are reported to present with multiple disorders (eg, congenital heart defects, particularly atrioventricular septal defect, leukemia, and early-onset Alzheimer disease [OMIM 190685]). A cytogenetic study showed that, in the United States, most infants with DS (∼95%) had full trisomy 21; in ∼3% of patients, one copy was translocated to another acrocentric chromosome, and in ∼2% of cases, live-born trisomy 21 individuals were recognized to have mosaicism for a trisomic cell line. Mosaicism results from the abnormal division of some cells after fertilization, with some of the cells having 47 chromosomes and the others being normal. In each of these conditions, the outcome of this disorder is determined by the particular chromosome being duplicated, as well as by the proportion of cells in the body carrying the abnormality. Papavassiliou et al observed a correlation between the frequency of trisomic cells and the patient phenotype. They detected a significant inverse correlation between the frequency of trisomic cells and IQ scores in individuals with mosaic trisomy 21. Mosaic trisomies have also been reported on other chromosomes, such as chromosomes 1, 8, 9, 13, 16, 17, 18, and 22 (as reviewed by Poduri et al). Many attempts have been made to model DS to investigate the detailed pathophysiology of the condition. Generally, biopsy samples of brains are not available from patients, and thus, mouse models are currently the primary tools used to study the pathogenesis of DS. However, brain development differs in mice and humans. Although some human ES cells with trisomy 21 have been generated, the establishment of human ES cells from patients with DS remains ethically challenging.

**Capturing Trisomic and Disomic Cells From Mosaic Patients Using the iPS Cell Technology: DS as an Example**

DS/trisomy 21 patient-specific iPS cell lines have been generated from various cases, including mosaic patients. Recently, 2 groups reported the generation of iPS cell lines from fibroblasts that were derived from patients with DS with mosaicism. They confirmed that the trisomy 21 karyotype was present in the DS iPS cells; however, they also captured iPS cell lines from the patient’s fibroblasts, which were found to possess a disomic karyotype. This seemed to be the result of the reprogramming of euploid cells from the mosaic donor’s fibroblast population. DNA profiling of the corresponding cell lines revealed that these disomic and trisomic cell lines actually came from the same donor. The patient’s disomic cell line provides an ideal experimental control, because it can be used to cancel the noise in the genetic background that is often observed using so-called “healthy” individuals as controls. This system presents a powerful method for analyzing multiple genotype–phenotype associations in complex diseases that harbor multiple candidate mutations, such as chromosomal aberrations (Figure).

**Somatic Mosaicism in CINCA Syndrome**

Besides DS, patient-specific iPS cell lines have also been generated from the somatic cells of patients with autosomal mosaics of point mutations. For example, CINCA syndrome is a dominantly inherited autoinflammatory disease characterized by cutaneous symptoms, central nervous system involvement, and arthropathy (OMIM 607115). Saito et al described the first case of a patient with somatic mosaicism in their NLRP3 (also known as CIAS1) gene mutation. It has been observed that 30% to 40% of all patients have mutations in NLRP3 in only a small number (∼10%) of somatic cells, despite the fact that nearly half of all patients with CINCA syndrome carry heterozygous gain-of-function mutations of the gene. Recently, Tanaka et al generated both NLRP3 mutant and nonmutant iPS cell lines from patients with CINCA syndrome with somatic mosaicism and described their differentiation into macrophages. In this case, they succeeded in recapitulating the disease-relevant phenotype using only mutant macrophages derived from iPS cells, demonstrating that NLRP3-mutant macrophages are responsible for the pathogenesis of mosaic CINCA syndrome. Moreover, they succeeded in developing a drug screening system with the macrophages derived from iPS cells and illustrated the usefulness of iPS cell technology as a platform for drug discovery.

**A New Approach to Studying Somatic Mutations Using the iPS Cell Technology**

Recently, somatic mosaicism has been reported in a variety of tissues from healthy individuals, suggesting that it has physiological functions. In such cases, iPS cell technology can provide a universally applicable strategy to capture these somatic mosaics in human populations, allowing their impact to be evaluated.

Evidence from recent studies using single-nucleotide polymorphism microarrays or the next-generation sequencing technology demonstrates that a certain proportion of mutations that are detected in iPS cells come from the heterogeneous donor cell population, attributable to somatic mosaicism. The cells that carry pre-existing genetic alterations, such as single-nucleotide variants and copy number variations, are captured by the cloning event through the reprogramming process.
These single-nucleotide variants and copy number variations in a minor population of somatic cells have to date been overlooked because of the difficulty in detecting them. However, applying iPS cell technology allows for improved detection of such low-level mosaicism.

**Somatic Mosaicsisms in Cardiovascular Diseases**

Systematic analyses of Leipzig heart collections have shown somatic mutations in several transcription factor genes (NKX2.5, TBX5, GATA4, and HEY2) associated with complex congenital heart diseases, including atrial septal, ventricular, and atrioventricular septal defects.62-64 In these cases, each mutation was detected in the affected heart tissues, but not in the normal heart tissues, of the same patients. In this situation, mutant cardiomyocytes can be provided by gene editing of wild-type iPS cell lines.

Another set of examples of mosaicism was found in somatic mutations associated with arrhythmia.62-64 Mosaicism in connexin 40 and connexin 43 is associated with atrial fibrillation.63,64 Interestingly, subcloning analysis estimated allelic frequencies of mutant alleles at 20% to 34% within the patient’s cardiac tissue specimens; however, these mutations were not detected in lymphocytes. Each mutant connexin-expressing cell was observed loss of contribution to gap junction formations, as well as electrophysiological functions.

To further investigate the pathophysiology of those atrial fibrillations with somatic mosaicism of connexins, modeling of in vitro cardiac syncytia in which each cardiomyocyte is individually expressing either wild-type or mutant connexins provides a powerful tool. Recently, Kadota et al65 created cardiomyocyte sheets from human iPS/ES cells. They demonstrated that these sheets are capable of generating re-entrant arrhythmia models when stimulated with high-frequency electric pulses and subsequently showed their usefulness for screening and testing drugs with antiarrhythmic potential. Although further technological improvements are needed, this approach can provide a more precise model for the mosaic cardiac syncytium. In this case, we may choose to obtain mutated cardiac cells by gene-editing technology based on unaffected/well-characterized iPS cells because to date mutant connexin 40–expressing and connexin 43–expressing cells have only been detected in patient cardiac tissues, which are difficult to obtain by biopsy.

**Concluding Remarks**

Somatic variants are known to be potentially responsible for various diseases. However, the extent of somatic variation may have been markedly underestimated.66

As we discussed above, iPS cell technology allows us to approach human biology with higher resolution at the cellular level through the cell cloning process, as part of the reprogramming process. This approach holds great promise for studies on the native human physiological processes, as well as the development and pathology of human diseases. For example, in patients with trisomy 21, acquired mosaicism was observed in adult patients.67 Although there are still several technical hurdles that have to be overcome, we may be able to analyze such a disease/environmental/aging association successfully at the molecular level by applying iPS cell technology. Moreover, iPS cell technology holds the potential to lead to new insights into the human physiology associated with somatic mosaicism.

**Acknowledgments**

We thank Drs Yoshinori Yoshida and Kazutoshi Takahashi for their valuable scientific discussions. We also thank Rie Kato and Yoko Miyake for their valuable administrative support.

**Sources of Funding**

This work was supported by a grant from the Funding Program for World-Leading Innovative Research and Development on Science and Technology (FIRST Program) of the Japanese Society for the Promotion of Science (JSPS) and by a grant from Research Center Network for Realization of Regenerative Medicine of the Japan Science and Technology Agency (JST).

**Disclosures**

S. Yamanaka is a member without salary of the scientific advisory boards of iPierian, iPS Academia Japan, Megakaryon Corporation, and HEALIOS K. K. Japan. The other author reports no conflicts.

**References**


17. Park IH, Arora N, Hsu H, Maherali N, Afsheldt T, Shimamura A, Lensen MW, Cowan C, Hochedlinger K, Daley GQ. Disease-specific induced pluri-


25. Mégababé A, Ravel A, Mircher C, Sturtz F, Grattau Y, Rethoré MO, Delabar JM, Mobley WC. The 50th anniversary of the discovery of trisomy 21: the past, present, and future of research and treatment of Down syn-

26. Shinn M, Sifidé C, Coree A. Survival of children with mosaic Down syn-


32. Feldmann J, Prieur AM, Quartier P, Berquin P, Certain S, Cortes E, Teillac-


35. Ananine G, Williams EC, Li H, Chang Q. Isogenic pairs of wild type and mutant induced pluripotent stem cell (iPSC) lines from Rett syndrome pa-

36. Nagata Y, Yamamura Perspectives for iPS Cell Technology 509


Perspectives for Induced Pluripotent Stem Cell Technology: New Insights Into Human Physiology Involved in Somatic Mosaicism

Naoki Nagata and Shinya Yamanaka

Circ Res. 2014;114:505-510
doi: 10.1161/CIRCRESAHA.114.303043

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/114/3/505

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/